+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

High-power potassium-titanyl-phosphate laser photoselective vaporization prostatectomy for symptomatic benign prostatic hyperplasia



High-power potassium-titanyl-phosphate laser photoselective vaporization prostatectomy for symptomatic benign prostatic hyperplasia



Journal of Endourology 22(6): 1311-1314



Potassium-titanyl-phosphate (KTP) laser photoselective vaporization prostatectomy (PVP) is a relatively new technology for the management of lower urinary-tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). We review our initial experience. We prospectively evaluated our initial 12-month experience with 80 W KTP laser PVP. All had American Urological Association symptom score (AUASS), American Society of Anesthesiologists (ASA) risk score, serum prostate-specific antigen (PSA), maximum flow rate (Qmax), and postvoid residual (PVR) determinations and transrectal ultrasonography. There were 160 consecutive patients identified, with a mean age of 69.7 years (range 34-88 yrs) and a mean ASA score of 2.4 (range 1-4). The mean prostate volume was 72.3 cm(3) (range 20.3-261 cm(3)), with a mean PSA level of 2.2 ng/mL (range 0.1-17.9 ng/mL). Mean laser time and energy usage were 33.4 minutes (range 4-165 min) and 99.0 kJ (range 11.3-524 kJ), respectively. All were outpatient procedures with 96 (60%) patients catheter-free at discharge. Twenty-eight patients need catheter drainage for 1 week. Urinary-tract infections developed in 13 patients. Fourteen patients had clinically insignificant hematuria for more than 1 week. Bladder neck contractures that necessitated intervention developed in three patients. Three patients had persistent urinary retention. No urethral strictures or urinary incontinence were noted. Mean AUASS decreased significantly from 23 to 13, 9, 8, 7, and 6 (P < 0.05) at 1, 4, 12, 24, and 52 weeks, respectively. Qmax and PVR values also showed statistically significant improvement. Our initial results demonstrate that KTP laser PVP is safe and effective for the management of LUTS secondary to BPH.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053548157

Download citation: RISBibTeXText

PMID: 18484893

DOI: 10.1089/end.2008.0140


Related references

High-power potassium-titanyl-phosphate or lithium triboride laser photoselective vaporization prostatectomy for benign prostatic hyperplasia: a systematic approach. Journal of Endourology 21(10): 1141-1144, 2007

Photoselective Vaporization Of The Prostate (Pvp) Using 80 Watt High Power Potassium-Titanyl-Phosphate (Ktp) Laser For Benign Prostatic Hyperplasia. The Japanese Journal of Urology 97(7): 815-822, 2006

High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology 64(6): 1155-1159, 2004

Photoselective vaporization of the prostate (PVP) using 80 watt high power potassium-titanyl-phosphate (KTP) laser for benign prostatic hyperplasia: the first fifty-seven patients in Japan. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 97(7): 815-822, 2006

Potassium-titanyl-phosphate (KTP)/lithium triboride (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH): A systematic approach. 2007

The Efficacy and Safety of Photoselective Vaporization of the Prostate with a Potassium-titanyl-phosphate Laser for Symptomatic Benign Prostatic Hyperplasia according to Prostate Size: 2-Year Surgical Outcomes. Korean Journal of Urology 51(5): 330-336, 2010

Safety and efficacy of the potassium-titanyl-phosphate laser and photoselective vaporization of the prostate for benign prostatic hyperplasia. Reviews in Urology 8(Suppl. 3): S16-S23, 2006

Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. Journal of Endourology 26(7): 878-883, 2012

High-power KTP photoselective laser vaporization prostatectomy for the treatment of benign prostatic hyperplasia in men with large prostates. Journal of Urology 169(4 Suppl.): 393, 2003

Intermediate outcomes of GreenLight HPS™ laser photoselective vaporization prostatectomy for symptomatic benign prostatic hyperplasia. Journal of Endourology 25(6): 1037-1041, 2011

Lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for symptomatic benign prostatic hyperplasia (BPH): Initial outcomes. European Urology Suppl.s 7(3): 203, 2008

Lithium triboride (LBO) laser photoselective vaporization prostatectomy (PVP) for symptomatic benign prostatic hyperplasia (BPH): Initial outcomes. Journal of Urology 179(4): 629, 2008

High-power KTP photoselective laser vaporization prostatectomy versus transurethral electrovaporization of the prostate for the treatment of benign prostatic hyperplasia A prospective comparative trial. Journal of Urology 171(4 Suppl.): 402, 2004

Experiences in the treatment of benign prostatic hyperplasia with high power potassium-titanyl-phosphate (KTP) laser. Wiadomosci Lekarskie 59(3-4): 196-198, 2006

Clinical outcome of potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy for benign prostate hyperplasia. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 92(4): 498-505, 2001